Overview

Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

Status:
Terminated
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This is a randomized Phase III study to evaluate the efficacy and safety of perifosine when added to the combination of bortezomib and dexamethasone in multiple myeloma patients who have relapsed on a prior bortezomib treatment regimen.
Phase:
Phase 3
Details
Lead Sponsor:
AEterna Zentaris
Collaborator:
Dana-Farber Cancer Institute
Treatments:
BB 1101
Bortezomib
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate